Clover Health Investments Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
48.9%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$3Bnext fiscal year
FY EPS (est.)
$0.14next fiscal year
Monitoring Framework
Key Performance Indicators
Medicare Advantage Membership Quarterly155.8K
Total Revenue Quarterly749.2MTarget: $2.81 billion - $2.92 billion
GAAP Net Income Quarterly27MTarget: $0 million - $20 million
Adjusted EBITDA Quarterly40MTarget: $50 million - $70 million
Insurance Benefits Expense Ratio (BER) Quarterly8,650.0%
Watch Items
- CMS Star Ratings Recalculation and LitigationTrigger: Recalculation of 2026 PPO plan Star Rating following court orderAction: Monitor the financial impact of the recalculated 4.5 Star rating on 2027 payment year bonus payments and revenue.
- Counterpart Health SaaS CommercializationTrigger: Announcements of new partnerships or commercial contracts built on Counterpart Health infrastructure, such as the HealthEx partnership.Action: Monitor the pacing and financial impact of Counterpart Health investments and partnerships on overall revenue and profitability.
- New Member Cohort Economics and PerformanceAction: Track new member cohort improvement and returning cohort performance, focusing on Clover Assistant coverage, PCP adoption, and operating leverage.
Research as of 20 Jun 2026